Objective To study the effects of using the Xinhuang Pian application to cure phlebitis after chemotherapy, and then make out the proper therapeutic regimen. Methods Divided 130 patients with phlebitis after chemotherapy into the experimental group ( 69 cases) and the control group ( 61 cases) randomly. The Xinhuang Pian application was used in the experimental group, while the routine nursing method was used in the control group. Results The curative ratio in the experimental group and the control group were 92.75% and 32.79% respectively, the significant different was existed between them,P

Objective To study the efficacy of Yunnan baiyao aerosol treatment for patients undergone percutaneous coronary intervention ( PCI) with subcutaneous hematoma .Methods Seventy patients undergone PCI with subcutaneous hematoma were chosen as the research objects and divided into the observation group (35 cases) and the control group (35 cases) according to the order of odd or even number of patients enrolled . The patients in the observation group were treated with Yunnan baiyao aerosol plus Yunnan baiyao aerosol insurance solution, and those in the control group were treated with wet dressing of magnesium sulfate (50%). The treatment effects , healing time and degree of pain relief of the two groups were compared .Results The total efficiency of the observation group was 97.1%, which was significantly better than 85.7 of the control group (χ2 =11.893, P<0.05).The healing time of the observation group was (3.6 ±0.8) days, which was significantly shorter than (5.3 ±1.1) days in the control group (t=7.382, P<0.05).After 3 days of the treatment, 4 patients in the observation group and 13 patients in the control group had the severe pain .The difference of the degree of pain relief between the observation group and the control group was statistically significant ( Z =-7.432, P <0.05 ).Conclusions Yunnan baiyao aerosol treatment to subcutaneous hematoma after PCI can rapidly and safely relieve pain , swelling and stasis .It can be operated and accepted by patients easily .And it is worthy of clinical application .

Objective: To explore the clinical features and risk factors of hepatic injury due to immune checkpoint inhibitors (CPI) therapy in malignant tumor. Methods: Data of 112 patients (64 men and 48 women) who received CPI between January 2016 and March 2019 in Chinese Academy of Medical Sciences and Peking Union Medical College Shenzhen Hospital, and Huazhong University of Science and Techology Union Shenzhen Hospital were retrospectively collected. The median age of these patients was 60 years. Results: Hepatic adverse events were observed in 30 patients out of 112 patients (26.8%). Among them, the incidence of grade 3-5 hepatic adverse events were 7.14% (8/112). The median time of hepatic adverse event occurrence was 3 weeks (2-30) after undergoing therapy. The results of univariate and multivariate analyses showed that liver cancer was attributed to the CPI induced hepatitis (P<0.05). Patients with severe hepatic injury got almost complete resolution after receiving methlprednisolone for 4 to 6 weeks. Conclusion Live cancer is the risk factor of CPI-related hepatic adverse events.